BMBradley J. Monk

Bradley J. Monk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bradley J. Monk has a total of 190 co-authors. Here are the top co-authors by number of shared publications:

  • John K. Chan

    Palo Alto Medical Foundation, San Francisco, CA

    5 shared publications
  • Robert A. Burger

    From the University of California Irvine, Chao Family Comprehensive Cancer Center, Orange; Women's and Children's Hospital, University of Southern California, Los Angeles, CA; Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute; Department of Biostatistics, University at Buffalo, Buffalo, NY; University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA; and University of Iowa, Iowa City, IA

    4 shared publications
  • Ignace Vergote

    University Hospital Leuven, Leuven Cancer Institute , Leuven, Belgium, European Union

    3 shared publications
  • Lyndsay J. Willmott

    3 shared publications
  • Amit Manulal Oza

    Princess Margaret Cancer Centre 2 Division of Medical Oncology and Hematology , Toronto, Canada

    2 shared publications
  • Ana Oaknin

    Vall d’Hebron Institute of Oncology (VHIO) 7 Medical Oncology Service, Vall d’Hebron Barcelona Hospital Campus, Instituto de Investigación Sanitaria Hospital Universitari Vall d’Hebron (IIS IR-HUVH) Barcelona, Spain

    2 shared publications

Latest Publications

  • Patient characteristics associated with obesity in an endometrial cancer patient: first steps towards the design of a weight loss intervention

    by Dominique Barnes, Kristin M. Shields, Lyndsay J. Willmott, John Farley, Bradley J. Monk, Dana Chase

  • Evaluating the cost-effectiveness of current FDA-approved PARP inhibitors for the treatment of recurrent ovarian cancer.

    by Juliet Elizabeth Wolford, Jiaru Bai, Ramez Hassef Eskander, Robin Keller, Lindsey E Minion, John K. Chan, Bradley J. Monk, Krishnansu Sujata Tewari

    5516 Background: Unlike approved IV administered therapies, Medicare is under no obligation to cover prescription medicines. We sought to evaluate the cost-effectiveness of the two FDA-approved orally administered PARP inhibitors (PARPi), olaparib and rucaparib. Methods: A Markov model was created in TreeAge Pro 2015 with nodes in the chain allowing patients to transition through response, hematological complications, non-hematological complications, progression, and death. Separately, the PARP inhibitors were compared with IV administered drugs approved for recurrent ovarian cancers including platinum-based, non-platinum, and bevacizumab-based regimens. Toxicity and mean PFS rates for the different agents were obtained from registration trial data. Costs of IV chemotherapy, managing toxicities, infusions, and supportive care were estimated using 2015 Medicare data. Incremental cost-effectiveness ratios (ICER) were calculated and survival was reported in quality adjusted life months. Results: Platinum-based combinations were the most cost-effective at $1,672/PFS mo as compared to non-platinum agents ($6,688/mo), bevacizumab-containing regimens ($12,482/mo), olaparib ($13,3731/mo), and rucaparib ($14,034/mo). Considering a cost of $114,478 for olaparib and $137,068 for rucaparib prior to progression, costs associated with PARPi were 7.1 to 8.3X more than platinum combinations. To better compare the registration trial data to PARPi data, probability was adjusted to 2nd line for rucaparib, revealing it’s ICERs’ of per month of life added to be $26,997 for bevacizumab, $17,757 for non-platinum, and $79,585 for platinums. Using the adjusted-to-2nd-line probabilities for olaparib, exhibited ICERs were $16,549 for bevacizumab, $25,637 for non-platinums and $72,083 for platinums. Conclusions: The high costs of PARPi were not balanced by costs of infusion and managing toxicities of IV drugs typically associated with lower response rates and shorter PFS in the recurrent space. Balancing incremental clinical benefit with novel therapies remains problematic and could widen disparities among those with limited access to care.


  • Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

    by Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt, Amit M. Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A. Ledermann, Domenica Lorusso, Ignace Vergote, et al.

    (ed from N Engl J Med 2016;375(22):2154–2164) The initial response rate to platinum and taxane treatment in patients with advanced ovarian cancer is high. However, the effectiveness of this regimen diminishes over time, and most patients relapse; with retreatment, relapses occur at shorter intervals until patient death.


  • The American Society of Clinical Oncology 2016 annual meeting: A review and summary of selected abstracts

    by Bobbie J. Rimel, Steven J. Gibson, Daniele A. Sumner, Bradley J. Monk

  • Weekly Versus Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

    by John K. Chan, Mark F. Brady, Richard T. Penson, Helen Huang, Michael J. Birrer, Joan L. Walker, Paul A. DiSilvestro, Stephen C. Rubin, Lainie P. Martin, Susan A. Davidson, et al.

  • A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy.

    by Antonio Gonzalez-Martin, Floor Jennishens Backes, Klaus H. Baumann, Dana Meredith Chase, Mathias Konrad Fehr, Robert L. Coleman, Gilles Freyer, Paul DiSilvestro, Ofer Lavie, Thomas J. Herzog, et al.

    TPS5606 Background: Niraparib is a highly selective PARP1/2 inhibitor that induces synthetic lethality in tumor cells with homologous recombination DNA repair deficiencies (HRD). Niraparib is administered orally once daily (QD) and may be taken without regard to meals, because food does not significantly affect the absorption or metabolism of niraparib. In a phase 1 study, niraparib was clinically active and well tolerated in patients with ovarian cancer. To address the need for novel therapies for recurrence, a randomized, double-blind phase 3 study is evaluating niraparib as maintenance treatment in patients with stage III/IV HRD+ ovarian, fallopian tube, or primary peritoneal cancer who responded to front-line platinum-based chemotherapy but are at high risk for progressive disease, based on cancer stage, use of neoadjuvant therapy, and residual disease after primary surgery. Methods: This multicenter trial is enrolling ≈305 patients with ovarian, fallopian tube, or peritoneal cancer.Eligible females are required to have histologically diagnosed stage III/IV cancer, an HRD+ tumor (myChoice HRD test), normal or > 90% decrease in CA-125 levels during front-line therapy, and no prior PARP inhibitor use. Patients who have undergone debulking surgery must have residual disease after primary surgery unless they received neoadjuvant therapy. Patients with a known history of myelodysplastic syndrome (MDS) or a baseline cytogenetic test result with a risk for a diagnosis of MDS or acute myeloid leukemia are excluded. Patients must have completed ≥ 4 cycles of platinum-based therapy and had a complete or partial RECIST response. Patients are randomized (2:1) to receive niraparib 300 mg QD or matched placebo in 28-day cycles. Tumors are assessed every 12 weeks per RECIST v1.1. The primary endpoint is progression-free survival (PFS) by blinded central review. After 258 PFS events, the study will have 90% power (one-sided a = 0.025) to detect an improvement in median PFS with hazard ratio = 0.65. Secondary endpoints are evaluation of overall survival, patient-reported outcomes, safety and tolerability, and time to progression on next therapy. Clinical trial information: NCT02655016.


  • A Markov model to evaluate cost-effectiveness of the PARP inhibitor, olaparib, for fourth-line treatment of recurrent ovarian cancer.

    by Juliet Elizabeth Wolford, Jiaru Bai, Ramez Hassef Eskander, Robin Keller, Lindsey Minion, John K. Chan, Bradley J. Monk, Krishnansu Sujata Tewari

    5563 Background: Evaluate cost-effectiveness of olaparib, an oral PARP inhibitor, which unlike many other drugs administered via IV infusion, is outside the sphere of Medicare coverage. Methods: With the exception of olaparib, only IV drugs approved for recurrent ovarian cancer were studied, including platinum-based, non-platinum, and bevacizumab-based regimens. Registration trial data was reviewed to estimate toxicity and PFS rates for the different agents. Medicare data for 2015 was used to determine the costs of IV chemotherapy as well as for managing toxicities, infusions, and supportive care. A Markov model was created in TreeAge Pro 2015. Nodes in the Markov chain allowed patients to transition through response, hematological complications, non-hematological complications, progression, and death. Incremental cost-effectiveness ratios (ICER) were calculated for each group. Survival for ovarian cancer was reported in quality adjusted life months, with the adjustment occurring from a baseline of having recurrent ovarian cancer during a given month. Results: Platinum-based combinations were most cost-effective at $1,672/PFS mo as compared to non-platinum agents ($6,688/mo), olaparib ($10,291/mo), and bevacizumab-containing regimens ($12,482/mo). By adding $81,108 prior to progression, costs associated with olaparib therapy were 5.3X more than platinum-based combinations. When using 4th line data, the only positive ICER using 4th line data was for non-platinum drugs ($35,567 extra cost for 1 PFS month). Using probability adjusted to 2ndline olaparib treatment, olaparib’s ICERs’ are $5,225 for bevacizumab, $16,347 for non-platinum, and $51,935 for platinum treatment. Conclusions: Despite an uncommonly high 34% response rate among germline BRCA+ patients with measurable, recurrent ovarian cancer, the high cost of olaparib was not balanced by costs of infusion and managing toxicities of IV drugs typically associated with 20% RR and hypothetically shorter time to progression in the 4th line setting. Reconciliation of incremental clinical benefits with new cost prohibitive therapies remains problematic.


  • Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer

    by Devansu Tewari, James J. Java, Ritu Salani, Deborah K. Armstrong, Maurie Markman, Thomas Herzog, Bradley J. Monk, John K. Chan

    Obstet Gynecol Surv 2015;70(8):505–506 The primary site of spread and failure in most cases of advanced epithelial ovarian carcinoma (EOC) is the peritoneum. Even in relapses, the disease is typically confined to the peritoneal cavity. Previous studies have found a 20-fold higher concentration of cisplatin in the peritoneum after intraperitoneal (IP) administration compared with that in plasma after intravenous (IV) administration.


    • 1 November 2014
      • Vol. 12  (11) , 737-48

    Development of a platform for systemic antiangiogenesis therapy for advanced cervical cancer.

    by Krishnansu S Tewari, Bradley J Monk

    Women with metastatic, recurrent, or persistent cervical carcinoma historically have had extremely limited treatment options. Systemic chemotherapy in these settings is predominantly palliative and has been associated with platinum resistance, nondurable responses, rapid progression of disease with deterioration in quality of life, and early death. At the cooperative group level, efforts to breach this clinical impasse have focused on incorporation of antiangiogenesis therapy, medical optimization, and identification of less toxic regimens. Gynecologic Oncology Group protocols 204 and 240, along with the Japanese Clinical Oncology Group protocol 0505, make up the pivotal phase 3 clinical trials that have provided 3 distinct treatment options. These options incorporate the antiangiogenesis humanized monoclonal antibody bevacizumab in combination with either a platinum-based or nonplatinum-based chemotherapy doublet. This review will highlight the development of bevacizumab in advanced cervical cancer and address the relevance of the survival gain obtained using antiangiogenesis therapy in this high-risk population.